


Reichert Surface Plasmon Resonance Used for the Study of Aptamer Based Macromolecules



Researchers at Penn State University have been studying aptamers for a number of years.¹ For their current research, they combined aptamers with proteins to create macromolecules that can both assemble and maintain molecular recognition under physiological conditions. This application is particularly interesting since most macromolecules do not maintain their molecular recognition properties when they assemble. While proteins can assemble, the ability to maintain molecular recognition was expected to be made possible by the use of aptamers. In addition, these new macromers were studied to see if they would afford sustained release of VEGF to promote wound healing in mice.²

Fibrinogen and an anti-vascular endothelial growth factor (VEGF) aptamer were used to synthesize a hybrid aptamer-fibrinogen macromer. Fibrinogen is a natural protein that can assemble to form fibrin hydrogels. Aptamers are single-stranded oligonucleotides with high affinities and specificities to target molecules. Aptamers can be selected from large libraries and form functional structures through high-fidelity base pairing. This intramolecular hybridization would not affect the functional conformation of the aptamer or protein in an aptamer-protein macromer. Thus, it has been hypothesized and then shown in this work that Fibrinogen- aptamer macromers both assemble and form Fibrin hydrogels and maintain their molecular recognition capability.²

A variety of analysis techniques were used by researchers to verify both the assembly and molecular recognition properties of the macromolecule they formed. The secondary structure of the macromer was studied with circular dichroism and the assembly was studied using electron microscopy. Surface plasmon resonance was the primary technique used to determine whether molecular recognition was maintained in the combined molecule and a Reichert SPR instrument was used to do the analysis. The

aptamer-Fibrin hydrogels were further studied to determine their roles in controlling continuous VEGF release and promoting cell growth both in vitro and in vivo. VEGF is a potent angiogenic growth factor and the in vivo study was performed by studying the growth of new blood vessels for skin wound healing in mice.²

Experimental

BACKGROUND

Vascular Endothelial Growth Factor (VEGF) was immobilized on a planar chip using standard amine coupling. After equilibration, different compounds were flowed over the surface including free Aptamers, native Fibrinogen, a Thiol- modified scrambled aptamers-fibrinogen macromer (used as a control), and the Aptamer-Fibrinogen macromer which was the focus of this study.

CONDITIONS:

Instrument: SR7500DC/Reichert2SPR

Sensor Chip: Planar

Running Buffer: PBST

Flow Rate: 25 μ L/min

Temperature: 25 °C

Target: VEGF




Figure 1

(a) Sensorgram and fit is an example of Fibrinogen- Aptamer binding to VEGF.

(b) Sensorgram and fit is an example of Aptamer alone binding to VEGF.

Analytes: native Fibrinogen, free aptamers, Aptamer- Fibrinogen, macromer and scrambled aptamers- Fibrinogen

Results

Researchers found that their Aptamer-Fibrinogen macromer showed the largest response of all the samples tested (even though the size is comparable to all the other samples except for the aptamer alone) and had a slightly lower affinity than the KD for the Aptamer alone binding to VEGF (they found a KD of 240 nM for the Aptamer-Fibrinogen macromer versus 160 nM for free aptamer – these values are considered to be of moderate affinity related to this type of research).² Other samples that were tested (scrambled aptamer-fibrinogen control and fibrinogen alone) showed only minimal binding and are not included in figure 1.

Summary

- An Anti-VEGF aptamer- Fibrinogen macromer bound to immobilized VEGF using SPR and its response had a similar affinity to aptamer alone. In addition, the Anti- VEGF aptamer- Fibrinogen macromer showed a 5-10 times larger response than aptamer alone, fibrinogen alone or scrambled aptamer- Fibrinogen even though all samples but the aptamer alone were about the same size.
- Reichert SPR results provided confirmation that molecular recognition was maintained for the aptamer-fibrinogen macromer.
- Results here are preliminary but the idea of combining an anti-VEGF aptamer with fibrinogen to form a macromer show promise in the fields of drug delivery and regenerative medicine. The Penn State macromer showed enhanced wound healing in mice due to the sustained release properties of the macromer hydrogel. Future research will involve the study and optimization of parameters. For instance, a higher affinity aptamer (perhaps 10-fold higher than the current KD (ca 10 nM)) should improve the release profile of the macromer hydrogel.²

References

1. Penn State website: sites.psu.edu/yxwanglab/research/
2. Nan Zhao, James Coyne, Ming Xu, Xiaolong Zhang, Akiho Suzuki, Peng Shi, Jinping Lai, Guo-Hua Fong, Na Xiong, and Yong Wang, "Assembly of Bifunctional Aptamer- Fibrinogen Macromer for VEGF Delivery and Skin Wound Healing," Chem. Mater., 2019, 31 (3), pp 1006–1015 DOI: 10.1021/acs.chemmater.8b04486.

Learn more about how Reichert pushes the limits of detection and sensitivity in label-free interaction. To improve the quality of your protein interaction research, visit www.ReichertSPR.com

®*Trademark of Reichert Technologies Company Notice: No freedom from infringement of any patent owned by Reichert or others is to be inferred. Because use conditions and applicable laws may differ from one location to another and may change with time, Customer is responsible for determining whether products and the information in this document are appropriate for Customer's use and for ensuring that Customer's workplace and disposal practices are in compliance with applicable laws and other government enactments. The product shown in this literature may not be available for sale and/or available in all geographies where Reichert is represented. The claims made may not have been approved for use in all countries. Reichert assumes no obligation or liability for the information in this document. References to "Reichert" or the "Company" mean the Reichert legal entity selling the products to Customer unless otherwise expressly noted. NO WARRANTIES ARE GIVEN; ALL IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE EXPRESSLY EXCLUDED.

Corporate Office
Reichert Technologies
3362 Walden Avenue
Buffalo, New York 14043, USA
Tel: +1 716-686-4500
Fax: +1 716-686-4555
Toll Free USA: 1-888-849-8955
reichertspr.lifesciences@ametek.com

European Service Center
Carl-von-Linde Str. 42-85716
Unterschleissheim/Munich, Germany
Tel: +49 89 315 8911 0
Fax: +49 89 315 891

www.reichertspr.com